SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation

References

• Summary of product characteristics – Avastin. www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf ( August 15, 2022).
   Google Scholar
• Ferrara N . VEGF as a therapeutic target in cancer. Oncology69, 11–16 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia J , HurwitzHI, SandlerABet al. Bevacizumab (Avastin) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev.86, 102017 (2020).
   PubMed Web of Science ®Google Scholar
• Medicare Part B Spending by Drug. https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-b-spending-by-drug ( August 16, 2022).
   Google Scholar
• Monk BJ , LammersPE, CartwrightT, JacobsI. Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey. Pharmaceuticals (Basel)10(1), 19 (2017).
   PubMedGoogle Scholar
• Li E , SchleifR, EdelenB. Hospital management of outpatient oncology treatment decisions: a survey to identify strategies and concerns. J. Oncol. Pract.9(5), e248–e254 (2013).
   PubMedGoogle Scholar
• Cherny N , SullivanR, TorodeJ, SaarM, EniuA. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann. Oncol.27(8), 1423–1443 (2016).
   PubMed Web of Science ®Google Scholar
• ACS CAN examination of cancer drug coverage and transparency in the health insurance marketplaces. www.fightcancer.org/sites/default/files/National%20Documents/QHP%20Formularies%20Analysis%20-%202017%20FINAL.pdf ( August 16, 2022).
   Google Scholar
• Nadler E , EckertB, NeumannPJ. Do oncologists believe new cancer drugs offer good value?The Oncologist11, 90–95 (2006).
   PubMed Web of Science ®Google Scholar
• Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer. www.nice.org.uk/guidance/ta212/resources/bevacizumab-in-combination-with-oxaliplatin-and-either-fluorouracil-plus-folinic-acid-or-capecitabine-for-the-treatment-of-metastatic-colorectal-cancer-pdf-82600246301893 ( August 17, 2022).
   Google Scholar
• Li E , SubramanianJ, AndersonS, ThomasD, MckinleyJ, JacobsIA. Development of biosimilars in an era of oncologic drug shortages. Drug Des. Devel. Ther.9, 3247–3255 (2015).
   PubMed Web of Science ®Google Scholar
• Makurvet FD . Biologics vs. small molecules: drug costs and patient access. Medicine in Drug Discovery9, 100075 (2021).
   Google Scholar
• Biosimilar and interchangeable products. www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products ( August 19, 2022).
   Google Scholar
• Guidelines on evaluation of similar biotherapeutic products (SBPs), Annex 2, TRS No 977. https://cdn.who.int/media/docs/default-source/biologicals/trs_977_annex_2.pdf?sfvrsn=e2389a69_3&download=true ( August 16, 2022).
   Google Scholar
• Biosimilars in the EU – Information guide for healthcare professionals. www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf ( August 15, 2022).
   Google Scholar
• Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf ( August 17, 2022).
   Google Scholar
• Considerations in demonstrating interchangeability with a reference product – guidance for industry. www.fda.gov/media/124907/download ( August 19, 2022).
   Google Scholar
• The impact of biosimilar competition in Europe. www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf ( August 17, 2022).
   Google Scholar
• Calleja MA , AlbanellJ, ArandaEet al. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. Eur. J. Hosp. Pharm.doi:10.1136/ejhpharm-2021-002955 (2021).
   PubMedGoogle Scholar
• Jha A , UptonA, DunlopWC, AkehurstR. The budget impact of biosimilar Infliximab (Remsima(R)) for the treatment of autoimmune diseases in five European countries. Adv. Ther.32(8), 742–756 (2015).
   PubMed Web of Science ®Google Scholar
• NHS set to save record £300 million on the NHS’s highest drug spend. www.england.nhs.uk/2018/11/nhs-set-to-save-record-300-million-on-the-nhss-highest-drug-spend/ ( August 17, 2022).
   Google Scholar
• Kvien TK , PatelK, StrandV. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin. Arthritis Rheum.52, 151939 (2022).
   PubMed Web of Science ®Google Scholar
• Mulcahy AW , HlavkaJP, CaseSR. Biosimilar cost savings in the United States. Rand Health Quarterly7(4), 3 (2018).
   PubMedGoogle Scholar
• Delivering on the potential of biosimilar medicines. www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf ( August 17, 2022).
   Google Scholar
• Reck M , LuftA, BondarenkoIet al. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer146, 12–18 (2020).
   PubMed Web of Science ®Google Scholar
• Shin D , LeeYJ, ChoiJ, LeeD, ParkM, PetkovaM. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Cancer Chemother. Pharmacol.86(4), 567–575 (2020).
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics – Aybintio. www.ema.europa.eu/en/documents/product-information/aybintio-epar-product-information_en.pdf ( August 16, 2022).
   Google Scholar
• Summary of product characteristics – Onbevzi. /www.ema.europa.eu/en/documents/product-information/onbevzi-epar-product-information_en.pdf ( August 16, 2022).
   Google Scholar
• Assessment summary information for biosimilar IPRP biosimilars WG (Onbevzi). www.mfds.go.kr/com/file/down.do?dnCd=eng&fileNm=PASIB_Onbevzi(MFDS).pdf&filePath=contents/ ( August 16, 2022).
   Google Scholar
• Drug submission status Aybintio. www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/subm_stat_reports/pdf/aybintio.pdf ( August 16, 2022).
   Google Scholar
• Onbevci – License details. https://info.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=60001193 ( September 29, 2022).
   Google Scholar
• Wang J , ChowSC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel)5(4), 353–368 (2012).
   PubMedGoogle Scholar
• Scientific considerations in demonstrating biosimilarity to a reference product. www.fda.gov/media/82647/download ( August 18, 2022).
   Google Scholar
• Markus R , LiuJ, RamchandaniM, LandaD, BornT, KaurP. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs31(3), 175–187 (2017).
   PubMed Web of Science ®Google Scholar
• Assessment report – Aybintio. www.ema.europa.eu/en/documents/assessment-report/aybintio-epar-public-assessment-report_en.pdf ( November 3, 2022).
   Google Scholar
• Weise M , KurkiP, Wolff-HolzE, BielskyMC, SchneiderCK. Biosimilars: the science of extrapolation. Blood124(22), 3191–3196 (2014).
   PubMed Web of Science ®Google Scholar
• Kurki P , BarryS, BourgesI, TsantiliP, Wolff-HolzE. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs81(16), 1881–1896 (2021).
   PubMed Web of Science ®Google Scholar
• Greene L , SinghRM, CardenMJ, PardoCO, LichtensteinGR. Strategies for overcoming barriers to adopting biosimilars and achieving goals of the biologics price competition and innovation: a survey of managed care and speciality pharmacy professionals. J. Manag. Care Spec. Pharm.25(8), 904–912 (2019).
   PubMed Web of Science ®Google Scholar
• Teeple A , EllisLA, HuffLet al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr. Med. Res. Opin.35(4), 611–617 (2019).
   PubMed Web of Science ®Google Scholar
• Aladul MI , FitzpatrickRW, ChapmanSR. Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open8(11), e023603 (2018).
   PubMed Web of Science ®Google Scholar
• Leonard E , WascovichM, OskoueiS, GurzP, CarpenterD. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J. Manag. Care Spec. Pharm.25(1), 102–112 (2019).
   PubMed Web of Science ®Google Scholar
• Park SK , MoonW, KimES, ParkSH, ParkDI. Knowledge and viewpoints on biosimilar monoclonal antibodies among Asian physicians: comparison with European physicians. Korean J. Gastroenterol.74(6), 333–340 (2019).
   PubMedGoogle Scholar
• Hadoussa S , BouhlelM, SoussiMA, DriraC, HadoussaM, KhroufMR. Perception of hematologists and oncologists about the biosimilars: a prospective Tunisian study based on a survey. J. Oncol. Pharm. Pract.26(1), 124–132 (2020).
   PubMed Web of Science ®Google Scholar
• Sarnola K , MerikoskiM, JyrkkaJ, Hameen-AnttilaK. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open10(5), e034183 (2020).
   PubMed Web of Science ®Google Scholar
• Giuliani R , TaberneroJ, CardosoF, McgregorKH, VyasM, DeVries EGE. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open4(2), e000460 (2019).
   PubMed Web of Science ®Google Scholar
• Biosimilars of bevacizumab. https://gabionline.net/biosimilars/general/Biosimilars-of-bevacizumab ( August 22, 2022).
   Google Scholar
• Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf ( August 22, 2022).
   Google Scholar
• Saltz LB , ClarkeS, Diaz-RubioEet al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Melosky B , ReardonDA, NixonAB, SubramanianJ, BairAH, JacobsI. Bavacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol.14(24), 2507–2520 (2018).
   PubMed Web of Science ®Google Scholar
• Background information for the Oncologic Drugs Advisory Committee 13 July 2017 – Biologics License Application for ABP215. https://fda.report/media/106549/Amgen-Briefing-Information-for-the-July-13--2017-Meeting-of-the-Oncologic-Drugs-Advisory-Committee.pdf ( August 22, 2022).
   Google Scholar
• Lu JF , BrunoR, EpplerS, NovotnyW, LumB, GaudreaultJ. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol.62(5), 779–786 (2008).
   PubMed Web of Science ®Google Scholar
• Han K , PeyretT, MarchandMet al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother. Pharmacol.78(2), 341–351 (2016).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI , FehrenbachL, NovotnyWet al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N. Engl. J. Med350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F , HurwitzHI, FehrenbacherLet al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21(1), 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF , SchulzJ, MccleodMet al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol.23(16), 3697–3705 (2005).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ , CatalanoPJ, MeropolNJet al. Bevacizumab in combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Bennouna J , SastreJ, ArnoldDet al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology14(1), 29–37 (2013).
   PubMed Web of Science ®Google Scholar
• Gray R , BhattacharyaS, BowdenC, MillerK, ComisRL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J. Clin. Oncol.27(30), 4966–4972 (2009).
   PubMed Web of Science ®Google Scholar
• Robert NJ , DierasV, GlaspyJet al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol.29(10), 1252–1260 (2011).
   PubMed Web of Science ®Google Scholar
• Sandler AB , GrayR, PerryMCet al. Paclitaxel-Carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Leighl NB , ZatloukalP, MezgerJet al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 Study (AVAiL). J. Clin. Oncol.5(12), 1970–1976 (2010).
   Google Scholar
• Seto T , KatoT, NishioMet al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol.15(11), 1236–1244 (2014).
   PubMed Web of Science ®Google Scholar
• Escudier B , PluzanskaA, KoralewskiPet al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Bukowski RM , KabbinavarFF, FiglinRAet al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol.25(29), 4536–4541 (2007).
   PubMed Web of Science ®Google Scholar
• Tewari KS , BurgerRA, EnserroDet al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol.37(26), 2317–2328 (2019).
   PubMed Web of Science ®Google Scholar
• Perren TJ , SwartAM, PfistererJet al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med365(26), 2484–2496 (2011).
   PubMed Web of Science ®Google Scholar
• Aghajanian C , BlankSV, GoffBAet al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol.30(17), 2039–2045 (2012).
   PubMed Web of Science ®Google Scholar
• Coleman RL , BradyMF, HerzogTJet al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.18(6), 779–791 (2017).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E , HilpertF, WeberBet al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol.32(13), 1302–1308 (2014).
   PubMed Web of Science ®Google Scholar
• Tewari KS , SillMW, LongHJ3rdet al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med.370(8), 734–743 (2014).
   PubMed Web of Science ®Google Scholar
• Miller K , WangM, GralowJet al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med357, 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Burger RA , BradyMF, BookmanMAet al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med365, 2473–2483 (2011).
   PubMed Web of Science ®Google Scholar
• Rosen LS , JacobsIA, BurkesRL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol.12(5), 599–610 (2017).
   PubMed Web of Science ®Google Scholar
• Rhodes W , DeclueRW, AccorttNet al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol.17(36), 5119–5127 (2021).
   PubMed Web of Science ®Google Scholar
• Jin R , MahtaniRL, AccorttN, LawrenceT, SandschaferD, Loaiza-BonillaA. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US. Ther. Adv. Med. Oncol.13, 17588359211041961 (2021).
   Web of Science ®Google Scholar
• Yang J , KeltonJM, ThompsonJ, JimenezJM, MaculaitisMC, ShelbayaA. Real-world usage of bevacizumab-bvzr biosimilar in US Oncology Practice. AJMC28(4), 160–166 (2022).
   Google Scholar
• Pham C , NiuF, DelateTet al. Real-world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients with metastatic colorectal cancer. ASCO Annual Meeting I17(36), 5119–5127 (2022).
   Google Scholar
• Jin R , OgbomoAS, AccorttNet al. Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb. ASCO Annual Meeting I40(Suppl. 16), e15581–e15581 (2022).
   Google Scholar
• Prescribing information Avastin. www.gene.com/download/pdf/avastin_prescribing.pdf ( August 17, 2022).
   Google Scholar
• Park D , KimJ, YunJ, ParkSJ. Evaluation of the physico-chemical and biological stability of SB8 (Aybintio), a proposed biosimilar to bevacizumab, under ambient and in-use conditions. Adv. Ther.37(10), 4308–4324 (2020).
   PubMed Web of Science ®Google Scholar
• Goldschmidt J , HanesV. The totality of evidence and use of ABP 215, a biosimilar to bevacizumab. Oncol. Ther.9(1), 213–223 (2021).
   PubMed Web of Science ®Google Scholar
• Arvinte T , PalaisC, PoirierEet al. Part 2: physicochemical characterization of bevacizumab in 2mg/ml antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate. J. Pharm. Biomed. Anal.176, 112802 (2019).
   PubMed Web of Science ®Google Scholar
• Abdel-Tawab M , WassmuthM, GegenfurtnerFet al. Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials. Eur. J. Hosp. Pharm.doi:10.1136/ejhpharm-2021-003198 (2022).
   PubMedGoogle Scholar
• Biosimilars approved in Europe. www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe ( August 26, 2022).
   Google Scholar
• FDA-approved biosimilar products. www.fda.gov/drugs/biosimilars/biosimilar-product-information ( August 26, 2022).
   Google Scholar